oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Mammographic screening for breast cancer: What cancers do we find?
Department of Surgery, University Hospital, Uppsala, Sweden; Department of Cancer Epidemiology, University Hospital, Uppsala, Sweden; Department of Surgery, Kullbergska Hospital, Katrineholm, Sweden.
Department of Diagnostic Radiology, University Hospital, Uppsala, Sweden.
Department of Cancer Epidemiology, University Hospital, Uppsala, Sweden; Primary Health Care Centre, Skoghall, Sweden.ORCID iD: 0000-0003-4241-7851
Department of Pathology, University Hospital, Uppsala, Sweden; Department of Pathology, Central Hospital, Falun, Sweden.
Show others and affiliations
1997 (English)In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 33, no 4, 624-628 p.Article in journal (Refereed) Published
Abstract [en]

The aim of this study was to compare lymph node involvement of breast cancer cases detected at mammography screening with clinically-detected cases. During a 3-year period, 273 primary breast cancers were detected in a population-based screening programme, and 149 primary breast cancers were diagnosed clinically. Lymph node involvement was evaluated in univariate and multivariate logistic regression models correcting for tumour size, histological grade, steroid receptor status and DNA-ploidy. Patients with screen-detected cancers had a low relative risk of having lymph node metastases (univariate, OR = 0.31; 95% confidence interval = 0.19-0.52). In the multivariate logistic regression model, the relative risk was halved (OR = 0.47; 0.28-0.78). The reduced risk was more pronounced for women younger than 50 years of age compared to older women. The risk for screen-detected cases of having lymph node metastases at diagnosis was statistically significantly lower than for clinically-detected cases. The marked reduction, even when correcting for tumour size, makes it less likely that factors such as detection of clinically innocent tumours, length bias sampling or clinical symptoms related to axillary metastases can explain the whole difference. The results indicate at least part of the effect may be explained by tumour progression in the late preclinical detectable phase.

Place, publisher, year, edition, pages
Elsevier, 1997. Vol. 33, no 4, 624-628 p.
Keyword [en]
breast neoplasms; mammography; mass screening
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
URN: urn:nbn:se:oru:diva-55838DOI: 10.1016/S0959-8049(96)00482-0ISI: A1997WZ55700031PubMedID: 9274445Scopus ID: 2-s2.0-0030969233OAI: oai:DiVA.org:oru-55838DiVA: diva2:1075307
Available from: 2017-02-17 Created: 2017-02-17 Last updated: 2017-10-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Hasselgren, Mikael
In the same journal
European Journal of Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 16 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf